Hosted on MSN
Jefferies downgrades Replimune Group (REPL)
Fintel reports that on April 13, 2026, Jefferies downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Buy to Hold. Analyst Price Forecast Suggests 641.98% Upside As of April 9, 2026, the ...
Hosted on MSN
REPL stock lost 19% of its value today – why did the FDA refuse approval for its experimental melanoma drug?
・The FDA previously rejected approval for RP1 in July. ・The agency noted that the members of the team who reviewed the resubmission were different from those who reviewed the initial application to ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results